LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma |
University of Virginia, School of Medicine / Michael Engel, MD/PhD |
Reach Grants |
2016 |
Virginia |
Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma |
Virginia Commonwealth University / Anthony Faber, MD & Yael Mosse, MD (CHOP) |
Innovation Grants |
2015 |
Virginia |
Characterizing Resistance Mechanisms to BET-Bromodomain Inhibition in MYC-amplified |
Broad Institute / Rameen Beroukhim, MD,PhD |
Innovation Grants |
2015 |
Massachusetts |
Investigating phase separated condensates in FPD to MDS/AML progression |
Broad Institute / Zuzana Tothova, MD/PhD |
RUNX1 Early Career Investigator Grants |
2019 |
Massachusetts |
Building Capacity for the Clinical Trials Office at Children's Hospital of Wisconsin - Strengthening Phase I & II Trials Infrastructure |
Children's Hospital of Wisconsin - Milwaukee / Michael J. Burke, MD |
Phase I/II Infrastructure Grants |
2015 |
Wisconsin |
Role of Kindlin-3 In Natural Killer Cell Mediated Tumor Killing |
Children's Hospital of Wisconsin - Milwaukee / Nathan Schloemer, MD |
Young Investigator Grants |
2016 |
Wisconsin |
Phase I Study of Lentivirus Engineered Autologous AML Cells Expressing IL-12 in Children and Young Adults with Relapsed AML |
Children's Hospital of Wisconsin - Milwaukee / Michael Burke, MD & Jeffrey Medin, MD/PhD |
Reach Grants |
2017 |
Wisconsin |
Development of MicroRNA-Nanoparticles to Treat Childhood Acute Leukemia Carrying MLL Rearrangements |
University of Cincinnati College of Medicine / Jianjun Chen, PhD |
Innovation Grants |
2013 |
Ohio |
Is SIRT5 a Therapy Target in Acute Lymphoblastic Leukemia? |
University of Utah / Michael Deininger, MD/PhD |
Innovation Grants |
2018 |
Utah |
Determining Social Risk Factors for Poor Outcomes in Pediatric Cancer Using Children’s Oncology Group Registries |
University of Utah / Anne Kirchhoff, PhD/MPH |
Epidemiology Grants |
2019 |
Utah |